Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 17/20 | 0.80 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5387755 | 1.00 | FAAH (0.80) | FAAHGAACNR1CNR2PLA2G4A | |
| SCHEMBL5384210 | 1.00 | FAAH (0.80) | FAAHGAACNR1CNR2PLA2G4A | |
| SCHEMBL8103910 | 0.91 | FAAH (0.80) | FAAHGAAMEN1KMT2A | |
| SCHEMBL8104102 | 0.91 | FAAH (0.80) | FAAHGAAMEN1KMT2A | |
| SCHEMBL8112613 | 0.91 | FAAH (0.80) | FAAHGAAMEN1KMT2A | |
| SCHEMBL14532898 | 0.89 | FAAH (1.00) | FAAHGAAMEN1KMT2A | |
| SCHEMBL5371583 | 0.89 | FAAH (1.00) | FAAHGAACNR1CNR2PLA2G4A | |
| SCHEMBL5370606 | 0.87 | FAAH (0.78) | FAAHCNR1CNR2PLA2G4A | |
| SCHEMBL14502383 | 0.87 | FAAH (0.78) | FAAHCNR1CNR2PLA2G4A | |
| SCHEMBL5378409 | 0.87 | FAAH (0.78) | FAAHCNR1CNR2PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39634-E1 | Bisarylimidazoly fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-15 | — | — | US | disclosed |
| US-RE39634-E1 | Bisarylimidazoly fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1389107-A4 | BISARYLIMIDAZOLYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1389107-A1 | BISARYLIMIDAZOLYL FATTY ACID AMIDE HYDROLASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-02-18 | — | — | EP | disclosed |
| US-6562846-B2 | Bisarylimidazolyl fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-13 | — | — | US | disclosed |
| US-20020188009-A1 | Bisarylimidazolyl fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-12 | — | — | US | disclosed |
| WO-2002087569-A1 | BISARYLIMIDAZOLYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188009-A1 | Bisarylimidazolyl fatty acid amide hydrolase inhibitors | FAAH, FAAH2, FASN | FAAH 1/4885GAA 395/4885CNR1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.